The Next Generation of Gene Editing Therapeutic Technologies

Genome Editing therapeutic platforms (e.g. zinc finger nucleases, TALENs, meganucleases) have existed for 25+ years. Since the advent of the CRISPR/Cas9 (“CRISPR 1.0”) Platform, the biomedical research community has developed a Base Editing Platform (“CRISPR 2.0”) and a Prime Editing (“CRISPR 3.0”), both of which are more precise in their edits and more versatile in treating different types of mutations. In addition, the community has developed other innovations that include RNA Editing Platforms and a Gene Writing Platform. This session will seek to provide an overview of next generation platforms with key innovators as they seek to advance the science despite private market, public market, regulatory, and reimbursement challenges